Quadrant Capital Group LLC 89bio, Inc. Transaction History

Quadrant Capital Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$6.66 - $16.03 $1,038 - $2,500	156 Added 325.0%	204 $2,000
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $2,394 - $3,086	-159 Reduced 76.81%	48 $0
Q1 2023 May 11, 2023	BUY	$10.48 - $16.94 $1,666 - $2,693	159 Added 331.25%	207 $3,000
Q4 2022 Feb 10, 2023	BUY	$5.52 - $12.73 $264 - $611	48 New	48 $0

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.